Evidence map›Paper›PMID 41809292›Full record

ArticleCureus2026

Optimizing Treatment in Refractory Copper Deficiency: A Case Report.

Bishara Jahshan, Rami B Moussa, Abdo Haddad

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bishara JahshanInternal Medicine, Winchester Medical Center, Winchester, USA.
Rami B MoussaInternal Medicine, Lake Erie College of Osteopathic Medicine, Erie, USA.
Abdo HaddadHematology and Oncology, Cleveland Clinic Fairview Hospital, Cleveland, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Copper deficiency, though rare, is increasingly observed in patients who have undergone Roux-en-Y gastric bypass due to impaired absorption in the stomach, proximal duodenum, and small intestine. Deficiency may manifest as anemia, cytopenias, and myeloneuropathy. Standard treatment includes oral or intravenous (IV) copper supplementation, with IV replacement preferred in cases of malabsorption. We present a case of treatment-resistant copper deficiency in a woman in her late forties with a history of Roux-en-Y gastric bypass and iron-deficiency anemia, who presented with lower extremity paresthesias. Laboratory evaluation revealed severe copper deficiency (serum copper: 10 µg/dL; normal 80-155 µg/dL). Despite oral supplementation and the standard IV copper regimen (2 mg daily for five days every four to six weeks) over a two-year period, her copper levels remained low. A revised regimen of IV copper at 2 mg twice weekly resulted in a rapid normalization of her copper levels. This case highlights the potential limitations of standard copper replacement protocols in post-gastric bypass patients. Adjusting the frequency of IV copper administration may improve outcomes in cases of refractory copper deficiency. Individualized treatment regimens should be considered when standard protocols are ineffective.

Indexed as

anemiacopper deficiencyhypocupremiaparenteral copper therapyroux-en y

Identifiers

PMID41809292
PMCPMC12968335

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.